Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137090 | 1.00 | OPRM1 (0.46) | OPRM1HTR2AKDM1AMAOANR1I2 | |
| SCHEMBL29605479 | 1.00 | OPRM1 (0.46) | OPRM1HTR2AKDM1AMAOANR1I2 | |
| SCHEMBL1019743 | 1.00 | OPRM1 (0.46) | OPRM1HTR2AKDM1AMAOANR1I2 | |
| SCHEMBL11461369 | 1.00 | OPRM1 (0.46) | OPRM1HTR2AKDM1AMAOANR1I2 | |
| Phenol SCHEMBL9660770 | 0.84 | OPRM1 (0.53) | OPRM1OPRD1OPRK1 | |
| Phenol SCHEMBL9660778 | 0.84 | OPRM1 (0.53) | OPRM1OPRD1OPRK1 | |
| SCHEMBL1477254 | 0.81 | OPRM1 (0.57) | OPRM1OPRD1OPRK1 | |
| SCHEMBL8784745 | 0.81 | OPRM1 (0.57) | OPRM1OPRD1OPRK1 | |
| SCHEMBL971919 | 0.81 | OPRM1 (0.57) | OPRM1OPRD1OPRK1 | |
| SCHEMBL4283706 | 0.81 | OPRM1 (0.57) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352693-A1 | COMPOSITIONS USING IRON EXCIPIENTS AND THEIR USES INCLUDING FOR THE TREATMENT OF CANCER | Zetagen Therapeutics, Inc. (US) | 2025-11-20 | — | — | US | disclosed |
| US-12403118-B1 | Cancer treatments using modified fatty acids and the carriers to administer them | Zetagen Therapeutics, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-12390551-B2 | Compositions using iron excipients and their uses including for the treatment of cancer | Zetagen Therapeutics, Inc. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-3903772-B1 | COMPOSITIONS COMRISING AN OPIOID GROWTH FACTOR RECEPTOR (OGFR) ANTAGONIST FOR USE IN PROMOTING BONE FORMATION AND IN THE TREATMENT OF CANCER. | UNIV NEW YORK STATE RES FOUND (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12310962-B2 | Methods and compositions for treating cancer | Zetagen Therapeutics, Inc. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12258561-B2 | Compositions and methods to promote bone formation and their uses including for the treatment of cancer | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250049784-A1 | METHODS OF TREATING PROSTATE CANCER OR METASTASIZED PROSTATE CANCER | Zetagen Therapeutics, Inc. (US) | 2025-02-13 | — | — | US | disclosed |
| US-20240277699-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | Zetagen Therapeutics, Inc. (US) | 2024-08-22 | — | — | US | disclosed |
| US-11980615-B2 | Methods and compositions for treating cancer | Zetagen Therapeutics, Inc. (US) | 2024-05-14 | — | — | US | disclosed |
| US-11957676-B1 | Controlled release formulation and minimally invasive method of administration to locally treat cancer | Zetagen Therapeutics, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20050203123-A1 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1363630-A2 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6559159-B2 | Detcting moduators of binding activity of preferential membrane proteins; obtain animal, incubate with modulator, monitor adjustment in activity from recptors | RESEARCH TRIANGLE INSTITUTE | 2003-05-06 | — | — | US | disclosed |
| US-20020143145-A1 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2002-10-03 | — | — | US | disclosed |
| US-20020132828-A1 | Kappa opioid receptor ligands | RESEARCH TRIANGLE INSTITUTE (US) | 2002-09-19 | — | — | US | disclosed |
| WO-2002053533-A2 | KAPPA OPIOID RECEPTOR LIGANDS | RESEARCH TRIANGLE INSTITUTE (US) | 2002-07-11 | — | — | WO | disclosed |
| US-4191771-A | NARCOTIC ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1980-03-04 | — | — | US | disclosed |
| US-4175197-A | 1,3,4-Trisubstituted-4-aryl-1,4,5,6-tetra-hydropyridines | ELI LILLY AND COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4115400-A | 1-Azoniabicyclo[3.1.0]hexanes | ELI LILLY AND COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4081450-A | 1,3,4-Trisubstituted-4-arylpiperidines and their preparation | ELI LILLY AND COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132828-A1 | Kappa opioid receptor ligands | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885HTR2A 471/4885KDM1A 3734/4885 |
| US-20020143145-A1 | Kappa opioid receptor ligands | OPRK1, OPRD1, OPRL1 | OPRM1 4/4885HTR2A 452/4885KDM1A 3122/4885 |
| US-20050203123-A1 | Substituted piperidine compounds and methods of their use | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885HTR2A 22/4885KDM1A 978/4885 |
| US-12403118-B1 | Cancer treatments using modified fatty acids and the carriers to administer them | PAK4, FFAR4, PIK3R4 | OPRM1 2852/4885HTR2A 3815/4885KDM1A 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.